1Angenieux C, Salamero J, Fricker D, et al. Common characteristics of the human and rhesus macaque CDe molecules: conservation of biochemical and biological properties during primate evolution. Immunogenetics, 2003, 54: 842-849.
2Busshoff U, Hein A, Iglesias A, et al. CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination. J Neuroimmunol, 2001, 113: 220-230.
3Cipriani B, Chen L, Hiromatsu K, et al. Upregulation of group 1 CD1 antigen presenting molecules in guinea pigs with experimental autoimmune encephalomyelitis: an immunohistochemical study.Brain Pathol, 2003, 13: 1-9.
4Van Blokland SC, Wierenga-Wolf AF, van Helden-Meeuwsen CG, et al. Professional antigen presenting cells in minor salivary glands in Sjogren′s syndrome:potential contribution to the histopathological diagnosis. Lab Investi, 2000, 80: 1935-1941.
5Calabi R, Jarvis M, Martin L, et al. Two classes of CDI genes.Eur J Immunol, 1989, 19: 285-292.
6Riese RJ, Shi GP, Villadangos J, et al. Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S.Immunity, 2001, 15: 909-919.
7Honey K, Benlagha K, Beers C, et al. Thymocyte expression of cathepsin L is essential for NKT cell development. Nat Immunol,2002, 3: 1069-1074.
8Zeng D, Lee MK, Tung J, et al. Cutting edge: a role for CD1 in the pathogensis of lupus in NZB/NZW mice. Immunol, 2000, 164:5000-5004.
9Sieling PA, Porcelli SA, Duong BT, et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CDlc. J Immunol, 2000, 165: 5338-5344.
10Yang JQ, Singh AK, Wilson MT, et al. Immunoregulatory role of CDd in the hydrocarbon oil-induced model of lupus nephritis. J Immumol, 2003, 171: 2142-2153.
2Berkers CR, Ovaa H. Immunotherapeutic potential for ceramidebased activators of iNKT cells. Elsevier Rev, 2005, 26: 252- 257.
3Hayakawa YD, Godfrey DI, Mark JS. Alpha-galactosylceramide: potential immunomodulatory activity and future application. Curr Med Hem, 2004, 11: 241-252.
4Kojo S, Adachi Y, Keino H, et al. Dysfunction of T cell receptor AV24AJ18^+, BV11^+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheuma, 2001, 44:1127- 1138.
5Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what's in a name. Nat Rev Immunol, 2004, 4: 31-37.
6Gombert JM, Herbelin A, Tancrede-Bohin E, et al. Early quanti- tative and functional deficiency of NK1^+-like thymocytes in the NOD mouse. Eur J Immunol, 1996, 6: 989-998.
7Naumov YN, Bahjat KS, Gausling R, et al. Activation of CDld- restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Nat Med, 2001, 7: 1052-1056.
8Singh AK, Wilson MT, Hong S, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med, 2001, 194:1801-1811.
9Yang JQ, Saxena V, Xu HL, et al. Repeated α-galactosylce- ramide administration results in expansion of NKT cells and alleviates inflammatory dermatitis in MRL-lpr/lpr Mice. J Immunol, 2003, 171: 4439-4446.
10Sumida T, Sakamoto A, Murata H, et al. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J Exp Med, 1995, 182:1163-1168.
